Sagt die FDA doch ja ....

zeig mir ein bild eines büros oder Labor


rr musst du selber überlegen ob du die Realität sehen willst oder nicht
genta ist für immer weg, und nicht nur ausgesetzt

warum nach so einer langen Zeit jetzt erst eine Sammelklage eingereicht wurde.
Hat man Lunte gerochen das vielleicht doch was aus der Firma noch zu holen ist?
Ich bin ganz gespannt wie die Verhandlung aus geht!!!

Man braucht kein Büro um eine Firma zu sein. Aber sie besitzen Patente für Medikamente.
Und die dürften noch was Wert sein. Bis die nicht vertickt sind besteht die Firma noch,auch wenn nur noch auf den Papier.  

nur, wenn du 2008 genta aktien hast

und genta ist pleite da kannse klage solange sie wollen

http://www.youtube.com/watch?v=Lguh9tQKFe4

deine Knete

von mir abkaufen. Natürlich für ein ehrlichen "Preis". LOL

ehrlich  & genta....  

du hast den ehrlichen "Preis" gezahlt

Jetzt nur noch zurück lehnen und Däumchen drehen.

genau

hast du mal wieder  clever gemacht

wenn man dir für jeden genta post 10 cent gezahlt hätte


wärste reich!


nur genutzt hats nix

Die Aktie ist nicht mehr handelbar.

achso.

www.google.de/.....1.1.26.mobile-gws-serp..7.2.797.A9p2JTZxDtk

Schon wieder.

Aber es heißt nicht genanese sondern:

http://www.youtube.com/watch?v=Lguh9tQKFe4

genanese

"Genasense" ​

langnese

lange Nase ziehen. LOL

http://www.google.de/imgres?imgurl=http://...=0CDYQ9QEwAQ&dur=112

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013

M2 via CMTX - Wed Sep 04, 9:05AM CDT


Article
Comments ()









Related Stocks
CELGZ - Celgene Corp.

Sym Last Chg Pct

CELGZ 8.18 -0.02 -0.24%
GNTAQ 0.0001 unch unch
PCYC 116.59 -1.99 -1.68%

Research and Markets (www.researchandmarkets.com/research/jmtqph/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013" report to their offering. 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL). Scope - A snapshot of the global therapeutic scenario for Refractory Chronic Lymphocytic Leukemia (CLL). - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics. Companies Mentioned Genta Incorporated Celgene Corporation Pharmacyclics, Inc. SBI Biotech Co., Ltd. For more information visit www.researchandmarkets.com/research/jmtqph/refractory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Oncology (www.researchandmarkets.com/...t_id=122&campaign_id=jmtqph)

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at www.presswire.com on the world wide web. Inquiries to info@m2.com.  

oT

investorshub.advfn.com/Genta-Inc-GNTAQ-970/

No news?